Observation of the Effect and Mechanism of Multi Tunnel Minimally Invasive Treatment for Xanthelasma Palpebrarum
Launched by FUZHOU FIRST GENERAL HOSPITAL SKIN DISEASE PREVENTION AND CONTROL HOSPITAL · Mar 5, 2025
Trial Information
Current as of August 19, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Heparin Sodium Injection Procedure:
1. Disinfect the XP and the area 1cm beyond the lesion margin three times using iodophor and cotton swabs.
2. Dilute heparin sodium with 0.9% saline to a concentration of 2500 - 5000 U/ml, preparing 0.1ml of liquid per 1cm² of lesion area.
3. Use a 1ml syringe to insert the needle near the edge of the lesion, the puncture site should preferably be close to the eyebrow, ensuring that the gauze cover post-injection does not obstruct the view.
4. The needle should reach the space between the epidermis and dermis layers, creating an "orange-peel appearance" ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Clinical diagnosis of xanthelasma palpebrarum
- • Must be able to receive heparin sodium injection and multi tunnel minimally invasive treatment
- Exclusion Criteria:
- • Hemophilia
- • Coronary heart disease
- • Myocardial infarction
- • Cerebral infarction
About Fuzhou First General Hospital Skin Disease Prevention And Control Hospital
Fuzhou First General Hospital Skin Disease Prevention and Control Hospital is a leading clinical research institution dedicated to advancing the understanding and treatment of skin diseases. With a focus on innovative therapeutic approaches and preventive measures, the hospital integrates patient care, research, and education to enhance outcomes in dermatological health. Equipped with state-of-the-art facilities and a team of experienced medical professionals, the hospital actively conducts clinical trials aimed at developing new therapies and improving existing treatments for various skin conditions. Its commitment to excellence in clinical research contributes significantly to the field of dermatology and the well-being of patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Fuzhou, Fujian, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported